CASTLE BIOSCIENCES INC
CSTLNasdaq
$24.16
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +29.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$722.1M
Enterprise Value
$484.2M
P/E
—
P/S
2.1
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
0.6%
Dividend Yield
—
Revenue (TTM)
$339.9M
Net Income (TTM)
-$12.8M
Free Cash Flow (TTM)
$4.5M
Gross Margin
—
Operating Margin
-9.8%
Net Margin
-3.8%
ROE
-2.8%
ROIC
-11.8%
Debt / Equity
0.0
Net Cash
$237.9M
Return 1Y
+38.9%
Company profile
Castle Biosciences, Inc. focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company was founded in 2007 and is headquartered in Friendswood, Texas.
- CEO
- Derek J. Maetzold
- Sector
- Services
- Industry
- Healthcare
- Employees
- 540
- Headquarters
- Texas
- Website
- castlebiosciences.com
Management & directors
- Maetzold Derek JPres. & Chief Exec. Officer
- Oelschlager Kristen MChief Operating Officer
- Juvenal Tobin WChief Commercial Officer
- Stokes FrankChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CSTL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$83.7M↓ -4.9%
Diluted EPS-$0.49↓ -45.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $62.6M | $94.1M | $137.0M | $219.8M | $332.1M | $344.2M |
| Gross profit | $53.0M | — | — | — | — | — |
| Operating income | -$6.5M | -$40.1M | -$72.9M | -$68.0M | $8.7M | -$42.8M |
| Net income | -$10.3M | -$31.3M | -$67.1M | -$57.5M | $18.2M | -$24.2M |
| Diluted EPS | -$0.54 | -$1.24 | -$2.58 | -$2.14 | $0.62 | -$0.83 |
| Operating cash flow | $9.9M | -$19.0M | -$41.7M | -$5.6M | $64.9M | $64.3M |
| Free cash flow | $5.1M | -$22.5M | -$47.3M | -$19.2M | $36.5M | $28.3M |
| Gross margin | 84.5% | — | — | — | — | — |
| Operating margin | -10.4% | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Net margin | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $87.0M | $85.8M | $86.3M | $88.0M | $86.2M | $83.0M | $87.0M | $83.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $5.0M | $5.1M | $4.0M | -$27.9M | -$4.3M | -$6.8M | -$3.8M | -$18.4M |
| Net income | $8.9M | $2.3M | $9.6M | -$25.8M | $4.5M | -$501,000.00 | -$2.3M | -$14.5M |
| Diluted EPS | $0.31 | $0.08 | $0.32 | -$0.90 | $0.15 | -$0.02 | -$0.06 | -$0.49 |
| Operating cash flow | $24.0M | $23.3M | $24.4M | -$6.0M | $20.8M | $22.6M | $26.9M | -$22.1M |
| Free cash flow | $18.8M | $17.0M | $16.8M | -$10.8M | $11.6M | $7.8M | $19.7M | -$34.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 5.8% | 5.9% | 4.7% | -31.7% | -4.9% | -8.2% | -4.4% | -22.0% |
| Net margin | 10.3% | 2.6% | 11.1% | -29.4% | 5.2% | -0.6% | -2.7% | -17.4% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 1,357 | $22.92 | $31,102.44 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 1,153 | $22.92 | $26,426.76 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 550 | $22.92 | $12,606.00 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $22.92 | $6,371.76 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $22.92 | $6,371.76 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $22.92 | $6,371.76 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $22.92 | $6,371.76 | filing |
| 2026-07-14 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Option exercise | 550 | $2.39 | $1,314.50 | filing |
| 2026-07-01 | Oelschlager Kristen M· Chief Operating Officer | Sale | 8,186 | $24.40 | $199,738.40 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 6,214 | $24.29 | $150,938.06 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 1,357 | $24.29 | $32,961.53 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 1,153 | $24.29 | $28,006.37 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Option exercise | 6,214 | $2.39 | $14,851.46 | filing |
| 2026-07-01 | Oelschlager Kristen M· Chief Operating Officer | Sale | 400 | $24.78 | $9,912.00 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $24.29 | $6,752.62 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $24.29 | $6,752.62 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $24.29 | $6,752.62 | filing |
| 2026-07-01 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $24.29 | $6,752.62 | filing |
| 2026-06-16 | Oelschlager Kristen M· Chief Operating Officer | Sale | 8,587 | $20.71 | $177,836.77 | filing |
| 2026-06-15 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 1,357 | $20.66 | $28,035.62 | filing |
| 2026-06-15 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 1,153 | $20.66 | $23,820.98 | filing |
| 2026-06-15 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 550 | $20.66 | $11,363.00 | filing |
| 2026-06-15 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $20.66 | $5,743.48 | filing |
| 2026-06-15 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $20.66 | $5,743.48 | filing |
| 2026-06-15 | MAETZOLD DEREK J· Pres. & Chief Exec. Officer | Sale | 278 | $20.66 | $5,743.48 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.